Here are four takeaways:
1. The agreement gives RTI an exclusive license to OPM’s OsteoFab technology platform for spinal applications in all U.S. markets.
2. Under the agreement, OPM will manufacture RTI’s spinal implant designs using OsteoFab technology, and RTI will oversee finishing steps, packaging, marketing and distribution of finished products.
3. OsteoFab is a next-generation implant manufacturing process using laser light and OPM’s OXPEKK polymer.
4. The OsteoFab process aims to create implants that are designed to enable bone ongrowth.
More articles on devices:
Minimally invasive SI joint fusion could save $1,000s: 2 new studies
Wenzel Spine receives FDA clearance for VariLift-LX: 4 points
Medtech to present ROSA robotic surgery brain system at annual meetings: 3 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
